GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on April 16, 2024, serves as an amendment to a previous announcement (RNS No 6709K) regarding Director/PDMR shareholdings. The filing corrects a typographical error in the share price reported for a specific transaction involving a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports solely on a specific share transaction:
- Instrument: Ordinary Shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment within an ISA.
- Transaction Date: April 12, 2024.
- Volume: 19 shares.
- Corrected Price: £16.3860 per share.
- Exchange: London Stock Exchange (XLON).
Material Changes
The only material change disclosed is the correction of the share price for the transaction executed by David Redfern, Chief Strategy Officer. All other details from the original announcement remain unchanged.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. It is strictly a regulatory correction of a shareholding disclosure.
Investor Verification Points
- Verify the corrected share price of £16.3860 for the April 12, 2024 transaction.
- Confirm the transaction volume of 19 shares for David Redfern.
- Note that this filing does not impact GSK Plc's overall financial performance or capital structure.